Abstract:Most psychiatric disorders are characterized by emotional memory or learning disturbances. Chronic mild stress (CMS) is a common animal model for stress-induced depression. Here we examined whether 3 days of treatment using the CB1/2 receptor agonist WIN55,212-2 could ameliorate the effects of CMS on emotional learning (ie, conditioned avoidance and extinction), long-term potentiation (LTP) in the hippocampal-accumbens pathway, and depression-like symptoms (ie, coping with stress behavior, anhedonia, and weight changes). We also examined whether the ameliorating effects of WIN55,212-2 on behavior and physiology after CMS are mediated by CB1 and glucocorticoid receptors (GRs). Rats were exposed to CMS or handled on days 1–21. The agonist WIN55,212-2 or vehicle were administered on days 19–21 (IP; 0.5 mg/kg) and behavioral and electrophysiological measures were taken on days 23 and 28. The CB1 receptor antagonist AM251 (IP; 0.3 mg/kg) or the GR antagonist RU-38486 (IP; 10 mg/kg) were co-administered with WIN55,212-2. Our results show that CMS significantly modified physiological and behavioral reactions, as observed by the impairment in avoidance extinction and LTP in the hippocampal-accumbens pathway, and the alterations in depression-like symptoms, such as coping with stress behavior, weight gain, and sucrose consumption. The most significant effect observed in this study was that 3 days of WIN55,212-2 administration prevented the CMS-induced alterations in emotional memory (ie, extinction) and plasticity. This effect was mediated by CB1 receptors as the CB1 receptor antagonist AM251 prevented the ameliorating effects of WIN55,212-2 on extinction and LTP. The GR antagonist RU-38486 also prevented the CMS-induced alterations in extinction and plasticity, and when co-administered with WIN55,212-2, the preventive effects after CMS were maintained. The findings suggest that enhancing cannabinoid signaling could represent a novel approach to the treatment of cognitive deficits that accompany stress-related depression.

Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2

The Cb1 Cannabinoid Receptor Agonist Reduces L-Dopa-Induced Motor Fluctuation and Erk1/2 Phosphorylation in 6-Ohda-lesioned Rats

Juvenile Cannabinoid Treatment Induces Frontostriatal Gliogenesis in Lewis Rats.

Somatic and anxiety-like behaviors in male and female rats during withdrawal from the non-selective cannabinoid agonist WIN 55,212–2

Adolescent Δ9-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats

Cannabinoid Receptor Activation Prevents the Effects of Chronic Mild Stress on Emotional Learning and LTP in a Rat Model of Depression

Indirect and direct cannabinoid agonists differentially affect mesolimbic dopamine release and related behaviors.

Effects of repeated voluntary oral consumption of synthetic delta-9-tetrahydrocannabinol on locomotor activity and cannabinoid receptor 1 expression

FUNCTIONAL CHANGES OF CB1 RECEPTOR IN RATS' NUCLEUS ACCUMBENS FOLLOWING SHORT-TERM WITHDRAWAL OF REPEATED MORPHINE EXPOSURE

Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2

Chronic Cocaine-Regulated Epigenomic Changes in Mouse Nucleus Accumbens.

CB2 agonist mitigates cocaine-induced reinstatement of place preference and modulates the inflammatory response in mice

Immune and glial cell alterations in the rat brain after repeated exposure to the synthetic cannabinoid JWH-018

CB1 Receptor Agonist WIN55212-2 Improves Motor Complications in Parkinson's Disease

A Synthetic Cannabinoid Agonist Promotes Oligodendrogliogenesis During Viral Encephalitis in Rats.

Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses

Effects of Cannabinoid CB1 Receptor Antagonist Rimonabant on Acquisition and Reinstatement of Psychostimulant Reward Memory in Mice

Effects of WIN55,212-2 on Voltage-Gated Sodium Channels in Trigeminal Ganglion Neurons of Rats

The Cannabinoid WIN 55,212-2 Reduces Delayed Neurologic Sequelae after Carbon Monoxide Poisoning by Promoting Microglial M2 Polarization Through ST2 Signaling

Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK.

Activation of the Cannabinoid Receptors Suppresses Hyperexcitation of Rat Hippocampal Neuronal Networks In Vitro